P-gp、MRP、LRP、P53及c-erbB-2在非小细胞肺癌中的表达

Objective: To investigate the expression of P-glycoprotein (P-gp), multidrug resistance-related protein (MRP), lung resistance-related protein (LRP), P53 and c-erbB-2 in untreated non-small cell lung cancer (NSCLC) and their relationship with each other. Methods: The expression of P-gp, MRP, LRP, P53 and c-erbB-2 was detected in the carcinoma tissues of 78 NSCLC patients and 15 adjacent normal lung tissues (5 cm apart from tumors) by means of immunohistochemistry. Results: The positive rates of P-gp, MRP, LRP, P53 and c-erbB-2 in tumor tissues were 65.4%, 39.7%, 56.4%, 53.8% and 43.6%, respectively, all significantly higher than those in normal tissues(P＜0.05). There was also significant difference in MRP and LRP expression between different pathologic types of NSCLC (squamous cell carcinoma, adenocarcinoma, large cell carcinoma) (P=0.008 and ＜0.001, respectively). Expression of LRP and P53 was also significantly different between different degrees of pathological differentiation (well, moderate, poor) (P=0.025 and 0.026, respectively). The expression of c-erbB-2 was correlated with those of P-gp, MRP, LRP and P53 (Spearman R=0.317, 0.401, 0.519 and 0.341, respectively; P=0.005, ＜0.001, ＜0.001 and =0.002, respectively); the expression of P53 was correlated with that of MRP (Spearman R=0.260, P=0.022); and the expression of LRP was correlated with that of MRP (Spearman R=0.371, P=0.001). Conclusion: Overexpression of P-gp, MRP, LRP, P53 and c-erbB-2 may play a cooperative role in the drug resistance and development of NSCLC.